Observational study on cancer cachexia subtypes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify distinct subtypes of cancer cachexia in patients with unresectable advanced colorectal, lung, or pancreatic cancers. It evaluates various factors such as symptoms, physical function, and blood biomarkers to understand the different causes of weight and muscle loss in these patients. Participants will complete surveys, undergo physical tests, and provide blood and tumor samples to build a comprehensive database that may inform future treatment strategies. The study also seeks to validate diagnostic phenotypes of cachexia and explore tumor-derived factors contributing to the condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have a primary diagnosis of unresectable or stage IV 1) non-small cell lung cancer (NSCLC), 2) pancreatic adenocarcinoma, or 3) colorectal cancer

  * Note: Patients do not need to have cachexia to be eligible
* Plan to start first-line systemic anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy, interventional clinical trial) in the next 6 weeks or has started first-line systemic therapy in the previous 6 weeks.

  * NOTE: Patients who received systemic anti-cancer therapy previously as part of adjuvant or neoadjuvant treatment and have since recurred are still eligible if such treatment ended \> 6 months prior to enrollment. Patients receiving concurrent radiation with systemic therapy or received local therapy alone (surgery, radiation therapy \[RT\]) prior to first line therapy remain eligible. Patients receiving maintenance treatment after first line therapy are not eligible
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
* Be able to understand, speak and read English
* Be 18 years of age or older

Exclusion Criteria:

* Have contraindications to physical function assessments (30-second arm curl, Timed-Up-And-Go test, or 30-second chair-stand test) per the treating provider or their designee
* Have any planned major surgeries within the next 3 months
* Have received chemotherapy or surgery for separate primary cancer within the past 3 years other than early local staged non-melanoma skin cancer
* Be pregnant

Where it's running

• Mercy Hospital Fort Smith
  Fort Smith, Arkansas, United States Recruiting
• Beebe South Coastal Health Campus
  Millville, Delaware, United States Recruiting
• Helen F Graham Cancer Center
  Newark, Delaware, United States Recruiting
• Medical Oncology Hematology Consultants PA
  Newark, Delaware, United States Recruiting
• Christiana Care Health System-Christiana Hospital
  Newark, Delaware, United States Recruiting
• Beebe Health Campus
  Rehoboth Beach, Delaware, United States Recruiting

+175 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Principal investigator: Richard F Dunne — University of Rochester NCORP Research Base

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understand cancer cachexia subtypes in advanced cancers

  This study tests how cancer cachexia presents in people with advanced colorectal, pancreatic, or lung cancer to see if different subtypes relate to outcomes.

  Recruiting Kaiser Permanente · Pleasanton, California · NCT07776353

• CPI-613 combined with hydroxychloroquine and chemotherapy for advanced solid tumors

  This study is testing a new combination of treatments, including CPI-613 and hydroxychloroquine, to see if it can help people with advanced solid tumors that haven't improved with other chemotherapy.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT05733000

• Morning versus afternoon immunotherapy for advanced or metastatic solid tumors

  This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07405086

• SX-682 with Atezolizumab for advanced or metastatic NSCLC

  This phase 2 trial tests whether combining SX-682 with atezolizumab can help people with advanced, metastatic, or recurrent NSCLC who have progressed after prior treatments.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07322341

• TR-002 (Nadofaragene Firadenovec) given by IV for adults with advanced unresectable or metastatic solid tumors and refractory metastatic pancreatic adenocarcinoma

  This Phase 1 trial tests whether weekly intravenous TR-002 is safe and what dose is best for adults with advanced unresectable or metastatic solid tumors or refractory metastatic pancreatic cancer.

  Recruiting Phase 1 University of California, Davis · Sacramento, California · NCT07189195

• GT103 plus pembrolizumab for advanced STK11‑mutant non‑small cell lung cancer

  This trial tests whether adding GT103 to pembrolizumab can help adults with advanced or metastatic STK11‑mutant non‑small cell lung cancer.

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT07017829

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.